Zepbound drug (tirzepatide) reduces sleep apnea severity in obesity patients, and Eli Lilly seeks FDA approval for expanded use.

A popular obesity drug, Zepbound, which contains the medication tirzepatide, has been found to help treat sleep apnea in a recent study. Tirzepatide reduced the severity of sleep apnea in patients with obesity who took the drug for a year, alongside reducing weight and improving blood pressure and other health measures. The drug's maker, Eli Lilly and Co., has requested the FDA to expand its use to treat moderate to severe sleep apnea, where people stop and start breathing during sleep, with a decision expected by the end of the year.

June 21, 2024
68 Articles

Further Reading